Harriet Park

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1

Kathryn E. Stephenson, Michael C. Keefer, Catherine A. Bunce et al. · PLoS ONE · 2018 · 36 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens

Julien Nyombayire, Omu Anzala, Brian Gazzard et al. · The Journal of Infectious Diseases · 2016 · 33 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial

Jonathan A. Robbins, Dereck Tait, Qinlei Huang et al. · EBioMedicine · 2022 · 24 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +10

Developing standards of care for HIV prevention research in developing countries – a case study of 10 research centers in Eastern and Southern Africa

Prince Bahati Ngongo, Frances Priddy, Harriet Park et al. · AIDS Care · 2012 · 18 citations

Public Health, Preventive Medicine, Public Health Practice +17